PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21672577-8	2011	By contrast, inhibition of DYRK1A (dual-specificity tyrosine-phosphorylation regulated kinase-1A) and CDK5 (cyclin-dependent kinase-5) reversed OKA-induced tau phosphorylation at certain sites but failed to prevent neuronal apoptosis.	Okadaic Acid	144-147	cyclin dependent kinase 5	Homo sapiens	102-106	
21672577-8	2011	By contrast, inhibition of DYRK1A (dual-specificity tyrosine-phosphorylation regulated kinase-1A) and CDK5 (cyclin-dependent kinase-5) reversed OKA-induced tau phosphorylation at certain sites but failed to prevent neuronal apoptosis.	Okadaic Acid	144-147	cyclin dependent kinase 5	Homo sapiens	108-133	
21435383-6	2011	In an okadaic acid-induced tau hyperphosphorylation SH-SY5Y cell model, the anti-tau-phosphorylation effect of VPA was further confirmed, accompanied by a marked decrease in the activities of CDK5 and GSK3beta.	Okadaic Acid	6-18	cyclin dependent kinase 5	Homo sapiens	192-196	
9599018-3	1998	In cells treated with 10 nM okadaic acid (OA), a PP-2A/PP-1 inhibitor, the PP-1 and -2A activities decreased by 60% and 100% respectively and the activities of MAPKs, cdc2 kinase and cdk5, but not of GSK-3, increased.	Okadaic Acid	28-40	cyclin dependent kinase 5	Homo sapiens	183-187	
21677377-4	2011	In addition, in cells expressing 3PO-tau, both the percentage of cells with aggregates, as well as the size of aggregates, was increased following overexpression of cdk5 or GSK3beta, decreased following treatment with pharmacological agents (roscovitine and lithium) active against these kinases, and increased following treatment with the phosphatase inhibitor okadaic acid.	Okadaic Acid	362-374	cyclin dependent kinase 5	Homo sapiens	165-169